|
News
2008 – 2007 – 2006 – 2005
June 24, 2008
Amorfix Acheives Target Sensitivity with its Alzheimer’s Disease Diagnostic Test
Amorfix Life Sciences today announced that its diagnostic test for the presence of aggregated Abeta in Alzheimer’s disease is ready to be applied to patient samples. The company has adapted its test to specifically detect aggregated Abeta protein (amyloid) in femtogram quantities (ten parts per trillion) from an Alzheimer’s brain when it is spiked into plasma or cerebral spinal fluid (CSF). More
June 13 , 2008
Amorfix Announces 2008 Year End Results
More
May 16, 2008
Amorfix to Webcast Presentation at the Rodman & Renshaw
5th Annual Global Healthcare Conference
Amorfix Life Sciences Ltd. today announced that Dr. George Adams, President and CEO, will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, Monaco.
The presentation will take place at 3:10pm local time (9:10am ET) on Monday, May 19th, 2008. A live webcast of the presentation can be accessed here. The presentation will be available for replay following the webcast. More
April 29, 2008
Amorfix Detects Scrapie Prions in Blood from Asymptomatic Sheep
Amorfix Life Sciences annouced today the detection of endogenous prions in the blood plasma of asymptomatic scrapie infected sheep. The company had previously reported detecting symptomatic sheep which was a requirement for testing of human vCJD in the United Kingdom. Scrapie, a disease in sheep similar to mad cow disease, is endemic in almost all the flocks of the 1 billion sheep in the world. Europe and North America have had programs to eradicate scrapie for many years and still have scrapie-infected herds. There were 76 newly-infected flocks in the United States in 2007. More
February 11, 2008
Amorfix Presents Results from British Blinded Panel of Spiked Human Blood Samples
Amorfix Life Sciences presented today the decoded results of a blinded panel of spiked human blood samples, tested by Amorfix’s EP-vCJDTM assay, at the 12th Annual Transmissible Spongiform Encephalopathies international conference. The samples had been provided by the British National Institute for Biological Standards and Control (NIBSC). More
February 8, 2008
Amorfix Releases Third Quarter Fiscal 2008 Results
More
February 1, 2008
UK Government Clarifies Process to Verify a Blood Test for vCJD and Releases Amorfix B Panel Results
Amorfix Life Sciences announced today that the Expert Advisory Group of the British National Institute for Biological Standards and Controls (NIBSC) has now established the process to verify the performance of an acceptable blood test for vCJD. Based on the performance of its EP-vCJD™ assay, Amorfix received and accepted an invitation from the British government to further qualify the assay using British blood samples. The NIBSC will provide blood samples from scrapie-infected sheep, normal human controls and patients with vCJD. More
January 10, 2008
Amorfix is Now a Member of the European Diagnostic Manufacturers Association
View EDMA's Press Release
January 4, 2008
Amorfix Appoints Aziz Mekouar as a Member of Board of Directors
Amorfix is pleased to announce the appointment of Aziz Mekouar to the company’s Board of Directors. “We are delighted to welcome Mr. Mekouar to our Board,” said Graham Strachan, Chair of the Board of Amorfix. “His substantial business experience and leadership in global affairs and with the United Nations will be an important asset as Amorfix continues to pursue its strategic objective of becoming a world leader in the treatment and diagnosis of misfolded-protein and prion diseases." More
|
